
QRxPharma announces several resignations
pharmafile | July 11, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Campbell, PACE, QRxPharma, farrell, quinn
Australian pharma development firm QRxPharma has confirmed that its chairman Dr Peter Farrell and director Dr Gary Pace have resigned.
Adding to the firm’s woes directors Peter Campbell and Michael Quinn have also tendered their resignations from its board, all seemingly resulting from difficulties with its pain drug Moxduo.
The company now expects Bruce Hancox and Dr Richard Treagus to be appointed as directors as a result following further consultation.
“It has been an honour serving as QRxPharma chairman and I certainly share the frustration of shareholders with respect to the development of Moxduo and interactions with the FDA,” said Dr Farrell (pictured).
At the firm’s general meeting Campbell added: “I would like to take this opportunity to thank my fellow board members, senior management and the entire QRxPharma staff and consultants in both Australia and the US for their commitment and efforts over the past seven years. The departing Board members wish the incoming board and shareholders of QRxPharma every success.”
Related Content
Scottish reforms proven to work says SMC
The chief pharma advisor for the Scottish Medicines Consortium Anne Lee says changes to its …

Changing our minds about depression
Alastair Campbell, former Labour spin doctor and depression patient, thinks that mental and physical health …

Mental and physical health should be treated equally
The need for a new approach to depression that gives it equal importance to physical …






